JW Therapeutics Announces License Agreement with Juno Amid Regulatory Approvals

An update from JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) is now available.

JW (Cayman) Therapeutics Co. Ltd. has entered into a License Agreement with Juno, a substantial shareholder and connected person, to grant a non-exclusive license for its sLVV Manufacturing Process and related know-how for Juno’s cell therapy products globally. This transaction is classified as a connected transaction under Hong Kong’s Listing Rules, requiring independent shareholder approval due to the significant percentage ratio involved. An independent board committee and financial adviser have been appointed to guide shareholders, and an Extraordinary General Meeting (EGM) will be held to seek approval. Juno and its associates will abstain from voting, and the transaction’s effectiveness is contingent upon meeting listing requirements.

More about JW (Cayman) Therapeutics Co. Ltd.

JW (Cayman) Therapeutics Co. Ltd. is a company incorporated in the Cayman Islands, operating in the biotechnology sector with a focus on cell therapy products. The company engages in the development, commercialization, and manufacturing of cell therapy products, leveraging proprietary manufacturing processes and related know-how.

YTD Price Performance: 13.28%

Average Trading Volume: 2,060,118

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$603.4M

For detailed information about 2126 stock, go to TipRanks’ Stock Analysis page.